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2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a ubiquitous environmental contaminant that is produced
inadvertently during the synthesis of some organochlorine compounds, such as the chlorinated phenoxy
pesticides. It is biologically and ecologically persistent, with an estimated half-life of 7 years in humans. It
possesseshighacutetoxicityinrodentsandisacarcinogen,teratogen,andimmunotoxin. Inchronicbioassays
for carcinogenicity, TCDD at a dose of 10 ng/kg/day increases the incidence of liver tumors in female rats,
making it one of the most potent animal carcinogens ever tested. A recent study in humans has shown an
increase in the incidence of respiratory tract tumors in workers in chlorinated phenoxy herbicide plants.
Considerable controversy and uncertainty remain, however, concerning its carcinogenic potency in humans
and the reliability ofusing animal data to predict human risks.
It isgenerally acceptedthatmost, ifnotall, ofthe effects ofTCDD require its bindingtotheAh receptor. In
addition to its toxic effects, TCDD produces a number of biochemical effects, such as induction of CYPlAl,
downregulation ofbindingactivityoftheestrogenandepidermalgrowthfactor(EGF) receptors, andchanges
in cytokine pathways. These effects suggestthattheAh receptorplays an importantrole in regulatingthe cell
cycle. Anumberofstructural analogs ofTCDD, such as the polychlorinated dibenzofurans, also interact with
the Ah receptor, and they produce the same spectrum of responses as TCDD in animal and cell models. The
potency ofthese compounds is strongly correlated with theirbinding affinity to theAh receptor. Perhaps the
most sensitive marker ofexposure to TCDD in both rodents and humans is induction ofa specific isozyme of
cytochrome P450 (CYPLA1). Our datasuggestthat humans are at least as sensitive as rats to CYPIAl enzyme
induction (produced by transcriptional activation of the CYPJAI gene) and to down-regulation of the EGF
receptor. Thisconclusion isbasedondataobtainedin vivo (accidentally exposed humans andrats subjectedto
a two-stage model ofhepatocarcinogenesis) and in vitro (incubation ofhuman and rodent lymphocytes with
TCDD).Thereisconsiderable interindividualvariationinhumanresponsestoTCDD.Ourworkon"markersof
susceptibility" suggests that bothvariation in the amount ofAh receptor and a mutation in the CYPLAI gene
may be responsible for this variation. Since TCDD gives negative results in short-term tests for genotoxicity
and does not bind covalently to DNA, it can be considered a prototypical chemical for the study of receptor-
mediated carcinogenesis
Introduction
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is pro-
duced inadvertently during the synthesis of some
organohalogen compounds, such as the herbicide 2,4,5-
trichlorophenol, and is formed as a by-product ofcombus-
tion ofchlorine-containing wastes and during the bleach-
ingofpaperpulpduring paperproduction. Overthelast20
years, this compound has received considerable attention
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because it is acutely toxic to experimental animals atvery
low doses and because ofits presence as a trace contami-
nantinfood,water, and soil. In guineapigs, TCDD has an
LD50 of 1 pLg/kg; other species are considerably less
sensitive to its acute toxic effects (1).
TCDD and its structural analogs, such as the poly-
chlorinated dibenzofurans (PCDFs), produce awide spec-
trum of effects in experimental animals, which include
teratogenicity, carcinogenicity, immunotoxicity, and a
variety ofbiochemical effectsinvolvingdrug-metabolizing
enzymes and growth factorpathways (2,3). Some ofthese
effects have been observed in humans exposed acciden-
tally or occupationally to TCDD or PCDFs.
Thispaperdealswiththemechanismofactionofdioxin,
comparative effects in humans and rodents, and dose-CLARK ET AL.
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FIGURE 1. Integrative approach forassessment ofriskforexposuretodioxins.Thisapproach attempts toincorporatedatafromexposuresto dioxins in
vivo and in vitro in both human and animal studies. PCB, polychlorinated biphenyl; PCDF, polychlorinated dibenzofuran; EGF, epidermal growth
factor; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; EROD, ethoxyresorufin-O-deethylase; AHH, arylhydrocarbon hydroxylase.
responserelationships forvariouseffects.Theseissuesare
discussed in relation to the potential use of biomarkers
(exposure, effect, and susceptibility) in evaluating poten-
tial adversehealth effects inhumans. Shownin Figure 1 is
our integrative approach to assimilate data from human
and animal studies following exposure both in vivo or in
vitro to TCDD or its structural analogs. End points
discussed include: a) evidence for carcinogenicity in epi-
demiological studies of accidentally exposed populations
and in carcinogenicity studies in laboratory animals; b)
biomarkers ofexposure, includingalterations ofbiochemi-
calparametersintissuesfromexposed humanpopulations
and from animal studies; and c) biomarkers of suscep-
tibilityafterexposures ofhuman andmurinelymphocytes
in vitro.
EvidenceforCarcinogenicity
of Dioxins from Human and
Animal Studies
Animal Carcinogenicity Data
There is convincing evidence that TCDD is a multisite
carcinogen. In chronic bioassays forits carcinogenicityin
rats, tumorincidenceswereincreased atanumberofsites.
Available studies on TCDD carcinogenesis have been
reviewed (4) and carcinogenic responses were seen after
either long-term or short-term exposures to TCDD in
every species studied. Tumors ofvarious types have been
induced in several organ systems, andthese do not appear
to be restricted to the site of application. In rats, TCDD
inducedneoplasms ofthelung,oraVnasalcavities, thyroid,
adrenal glands, and liver. In mice, TCDD caused neo-
plasmsoftheliver,subcutaneoustissue,andthyroidgland,
andlungandthymiclymphomas. Inhamsters, itproduced
squamous-cell carcinomas ofthefacial skin. Thmors ofthe
integumentary systemhavebeenreported after oral (rats
and mice), intraperitoneal (hamsters), and dermal (mice)
exposures. TCDDis atrans-species (rat, hamster,mouse),
trans-strain, trans-sex, multisite, complete carcinogen. It
induced carcinogenic effects in laboratory animals at
exposures as low as 0.01 ,ug/kg body weight/day in rat
liver and 0.001 ,ug/kg/day in rat thyroid and is clearly
among the most potent of all identified chemical car-
cinogens (4).
TCDD is ineffective in short-term tests for genetic
toxicity(5,6);moreover,itdoes notbindcovalentlyto DNA
either in in vitro or in vivo, even when methods are used
that can detect one adduct in 1011 normal nucleotides (7).
Therefore, TCDD is generally considered to be a non-
genotoxic carcinogen; however, it may exert indirect gen-
otoxic effects, as evidenced by one study in which TCDD
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increased the frequency of strand breaks in rat liver
nuclei, possibly byincreasing iron bioavailability and lipid
peroxidation (8).
There is strongevidence in experimental animalmodels
that TCDD is a tumor promoter and not an initiator,
although it must be kept in mind that the term "tumor
promoter" is an operational rather than a mechanistic
term. Inmultistagemodels forskinandlivercancer (9-11),
TCDD is a potent promoter but is virtually devoid of
initiating activity.
Both hepatocellular carcinomas and adenomas were
detected in atwo-stage model forhepatocarcinogenesis in
rats (a single initiating dose of N-nitrosodiethylamine
followed by chronic exposure to 100 ng/kg/day TCDD).
Interestingly, ovariectomy protected female ratliverfrom
the tumorpromoting actions ofTCDD (12). This findingis
consistentwith datafromchronicbioassayswhich demon-
stratedthatTCDDproduceslivertumorsinfemalebutnot
in male rats (13). The carcinogenicity data are also consis-
tent with those on cell proliferation, which showed that
TCDD increases cell proliferation rates in intact female
rats but not in ovariectomized rats (12). In contrast,
ovariectomy sensitized rats to the tumor promoting
actions of TCDD in lung (14). These findings add to the
growing amount of evidence that interactions of TCDD
with hormonallymediated events are a critical component
ofthe carcinogenic mechanisms ofthis chemical.
Human Cancer
Some reports in the literature indicate that exposure to
phenoxyacetic acid herbicides, chlorophenols, and chlo-
rinated dibenzodioxin contaminants, especially TCDD,
maybeassociatedwithhumancancer,includingmalignant
lymphomas, soft-tissue sarcomas, thyroid tumors, lung
tumors, and cancers at other sites (15). The International
Agency for Research on Cancer (IARC) (15) and the
National Institute for Occupational Safety and Health
(NIOSH) recently completed two pooled cohort studies.
The NIOSH registry covered workers with possible
exposure to TCDD during the manufacture/formation of
2,4,5-trichlorophenoxy acetic acid and 2,4,5-trichlorophenol.
The IARC registry included workers exposed to all types
of phenoxy acids and chlorophenols during manufacture
and use.
The incidence of thyroid tumors was elevated in the
IARC registry, and the risk was highest in workers with
probable TCDD exposure. An increased risk for all can-
cers combined was observed in the NIOSH registry, and
the risk increased with duration of exposure and latency.
The NIOSH registry showed an increased incidence of
respiratory tract cancers. Both the NIOSH and IARC
registersreported astatisticallynonsigniflcantincreasein
the incidence of soft-tissue sarcoma. Statistically signifi-
cant increases in liver tumor incidences were seen in
neither registry, which consisted primarily ofmen.
The human carcinogenicitydataare consistentwith the
animal data in several respects. First, increased inci-
dences ofthyroid tumors were detected in both rats and
humans. Second, liver tumor incidence was increased in
neither male rats nor human males. Third, increases in
lungtumorincidencewere evidentin the NIOSH registry
and in male rats.
Several issues confound human epidemiological studies
on the carcinogenicity of TCDD. Exposures in the work-
place occur as part ofcomplexmixtures, soitis difficult to
ascertain therole ofTCDD inincreasingtumorincidence.
Also, humans are exposed daily to several ubiquitous,
persistent structural analogs of dioxin, including the
PCDFsand somepolychlorinatedbiphenyls.Therefore,no
true control population exists. Furthermore, there is
increasingevidenceofagreatdealofinterindividualvaria-
tion in the magnitude ofbackground exposures.
The environmental contamination episode in Seveso,
Italy, in 1976 is a different exposure scenario than that
represented by the IARC and NIOSH registries; the
individuals in Seveso were exposed primarily to TCDD
and not to the numerous other chemicals experienced by
the NIOSH and IARC cohorts.Althoughthefollow-uphas
been only10-15years and therefore ofinsufficient latency,
some information on cancermortality has beenpublished.
The standardized mortality ratios were elevated for cer-
tain cancers, including soft-tissue sarcoma, Hodgkin's
disease, cancers of the gallbladder and bile duct, and
thyroid and otherendocrine-associated tumors (16).These
results are based on one to three deaths only, however,
making it difficult to establish patterns relating tumor
occurrence specifically to TCDD at this time.
Biomarkers for Exposure in Animals
and Humans
Animal Studies
Wehaveused achronic exposureregimenin the context
of a tumor promotion model with N-nitrosodiethylamine
as the initiating agent and TCDD as the promoter in
Sprague-Dawley rats to investigate dose-response rela-
tionships for biochemical responses and their association
with carcinogenic processes. Inthese experiments, female
rats received a single initiating dose of N-nitrosodi-
ethylamine followed by chronic exposure to TCDD by
gavage at doses ranging from 0.1 to 125 ng/kg/day for 30
weeks. Dose-response relationships for a number of bio-
chemical responses following exposure toTCDD are sum-
marized in Table 1. One ofthe most sensitive biochemical
markers for exposure to TCDD is induction ofCYPlAl in
the liver of exposed animals; exposures to as little as 0.1
ng/kg/day appear to produce detectable increases in
CYPlAl activity. Mathematical evaluation of this data
indicates that there is no apparent threshold for TCDD-
mediated induction of CYPlAl or CYP1A2 (17). Down-
regulation ofthe binding of EGF (epidermal growth fac-
tor) to its receptorfollowingTCDD exposurewas another
sensitive marker for TCDD-mediated effects, exhibiting
an ED50 of12 ng/kg/day, which is similar to the ED50s for
CYPlAl andCYP1A2induction. TCDD-mediated increas-
esincellproliferation, y-glutamyltranspeptidase-positive
foci, and serum 5'-nucleotidase were less sensitive for
detectingTCDD-mediatedeffects butmaybemore appro-
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Table 1. Comparative dose-response relationships for
TCDD-mediated effects in a tumor promotion model
(single initiating dose ofN-nitrosodiethylamine followed by
chronic TCDD exposure for 30 weeks).
Dose, ng/kg/day
Lowest Approximate
TCDD-mediated effect detectable effect ED50
CYPlAl induction 0.1 15
CYP1A2 induction 0.3 20
Cell proliferation 125 ND
Focia 125 ND
5'-Nucleotidase 35 ND
Epidermal growth factor receptor 3.5 12
Abbreviations: TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; ND, not
determined.
aProportion of liver occupied by -y-glutamyl transpeptidase-positive
foci.
priatemarkersforits carcinogenic effects. The concentra-
tions ofTCDD in liver were linearly related to the admin-
istered dose over the entire dose range.
Human Exposures
In Taiwan during 1979, awidespread poisoningincident
occurred due to ingestion of rice oil contaminated with
PCDFs. These compounds are structurally similar to
TCDD and are thought to share the same mechanism of
action: binding to the Ah receptor and induction of
pleiotropic responses. Placentas from women exposed to
contaminated rice oil were analyzed for EGF receptor
binding and EGF-stimulated autophosphorylation as well
as for CYPlAl activity; the data are displayed in Table 2
(18,19). The placentas from the exposed women showed
decreased EGF receptor autophosphorylation activity
although the numberofbindingsites was similartothatin
control samples. The number of detectable binding sites
forthe glucocorticoid receptor wasreduced intheexposed
womento42% ofthatinthecontrolindividuals. Inratsand
mice, glucocorticoid and EGF receptor binding is
decreased by TCDD treatment (20,21). Exposure to
PCDFs resulted in an approximately 100-fold induction of
CYPlAl-dependent enzyme (ethoxyresorufin-O-deethyl-
ase; EROD) activity over that in the unexposed control;
however, there was considerable interdividual variation in
the response (Table 2). Although CYPlAl induction
occurred onlyinplacentas ofwomenwhohadingested the
contaminated rice oil, the magnitude of induction in the
exposed individuals did not correlate with placental con-
centrations of polychlorinated biphenyls or of PCDF or
with decreased birthweights in offspring of exposed
mothers. These studies indicate that humans are at least
as sensitive as rats to many of the biochemical effects of
TCDD, including enzyme induction (19).
Biomarkers for Susceptibility in
Humans and Animals
Ah Receptor
Studies carried out largely in rodents indicate that
many of the toxic responses elicited by dioxin (including
the promotion oftumors) are mediated by a specific intra-
cellular receptor protein (designated the Ah or dioxin
receptor) (10,22). In certain strains of mice, TCDD-
mediated induction of CYPlAl segregates with a single
genetic locus (Ah) (23). TheAh locus has been postulated
to contain the structural gene forthe dioxin receptor. The
first published evidence for involvement of the dioxin
receptor in TCDD-dependent toxicity was an analysis of
the dose-dependency, stereospecificity, and genetic segre-
gation ofTCDD-induced thymic atrophy and fetal abnor-
malities in two prototype inbred mouse strains (24). Since
publication of that report, many studies have established
the involvement ofthe dioxin receptor in avariety oftoxic
responses elicited by TCDD, including epidermal hyper-
keratinization in mice and humans and tumor-promoting
activity in rodents. Most of the existing knowledge is
largely correlative, however, and does not provide specific
information on how this receptor functions to elicit the
biochemical changes in target cells that lead to the
observed pathological lesions.
Multiplecomplementation groupshavebeenidentifiedin
the TCDD-dependent induction of CYP1A1, suggesting
the involvement of more than one protein in this receptor-
mediated response (25). Recently, the complementary
DNA and part of a gene for a protein (designated arnt)
required for the cytosol-to-nucleus translocation of the
TCDD-dioxin receptor complex in murine hepatoma cells
were cloned (26). The protein was found to contain signifi-
cant homology to the consensus sequence for the basic
Table 2. Comparison ofplacental CYPLAl induction and polychlorinated dibenzofuran (PCDF) concentrations ofwomen exposed to
contaminated rice oil and birthweight oftheir offspring.
Ethoxyresorufin-0-deethylase,
pmole/min/mg protein Birthweight, g Total PCDF concentration
Exposed Controls Exposed Controls Exposed Controls
34 <1 2900 3500 NA <0.01
31 <1 2700 3500 0.7 <0.01
63 <1 3000 3250 0.9 <0.01
42 <1 2700 3400 0.5 <0.01
62 <1 3000 3100 NA <0.01
1 < 3100 3900 0.8 <0.01
43 <1 2700 3500 0.8 <0,01
11 <1 3100 2800 0.6 <0.01
50 <1 2500 3700 NA <0.01
NA, not analyzed.
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helix-loop-helix motif characteristic of proteins that bind
DNA as homo- or heterodimers.
Differences in sensitivity to TCDD have been well-
documented in mice. At least one determinant resides at
thelevel ofsignal recognition, i.e., binding ofTCDD to the
dioxin receptor (10). Studies carried out in human squa-
mous-cell carcinoma cell lines (27) and in early-passage
human thymic epithelial cells derived from different indi-
viduals (28) provide evidence for potential polymorphism
in the human dioxin receptor, which in turn results in
differential sensitivity to TCDD.
Exposures ofHuman and Murine
Lymphocytes in Vitro
Establishing dose-response relationships for TCDD-
mediated effects in vitro is oneimportant step in generat-
ing data useful in the evaluation of human sensitivity to
TCDD. Two reports have beenpublished ofdose-response
relationships for induction of arylhydrocarbon hydrox-
ylase (AHH)inhumanlymphocytes. Kouri and Ratrie (29)
reported an EC50 of 8 nM TCDD for induction of AHH
activity in mitogen-stimulated peripheral blood lympho-
cytes while Nagayama et al. (30) reported an EC50 of
approximately 12 nM TCDD in Epstein-Barr virus trans-
formed cell lines. Waithe et al. (31) analyzed the physico-
chemical characteristics of the Ah receptor from an
Epstein-Barr virus-transformed cell line and demon-
strated that the Kd for TCDD binding to theAh receptor
was 4.6 nM TCDD. Recently, Neubert et al. (32) reported
that human peripheral blood lymphocytes are exquisitely
sensitive to TCDD-mediated alterations in cell surface
markerexpression at doses as low as 0.1 pmole. Invarious
human breast carcinoma cell lines, a range ofinducibility
has been observed for transfected CAT constructs con-
taining the upstream regulatory region of the CYPlAl
genethe EC50 forthe responsevaryingfrom 0.4 to5.9 nM
TCDD(33).
To compare the sensitivity of human and murine lym-
phocytes to TCDD, we analyzed dose-response relation-
ships oflymphocytes for induction ofEROD activity: The
EC50 values and maximal responses for human lympho-
cytes and murine lymphocytes are shown in Table 3.
Exposure of human lymphocytes to TCDD resulted in a
dose-dependent increase in EROD activity, with an EC50
of1.8 + 0.8 nmole TCDD. The response was much greater
in human peripheral blood lymphocytes than in murine
splenic lymphocytes, although the EC50 for the response
was similar. Murine lymphocytes responded in a dose-
dependent manner to TCDD, with an EC50 of 1.3 + 0.3
nmole. This response correlates well with those to other
TCDD-mediated effects on murine lymphocytes. For
example, the EC50 for inhibition of antibody-producing
cells in vitro was 7 nM TCDD (34). Blank et al. (36) also
demonstrated that TCDD in doses of nanomoles inhibits
antibody synthesis and stimulation of EROD activity in
murine lymphocytes. Luster et al. (37) showed that
exposure ofmurine B lymphocytes in vitro to nanomolar
concentrations selectively inhibited antibody production.
Table 3. Ethoxyresorufin-O-deethylase (EROD) response of
murine and human lymphocytes to
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).
EROD activity,a pmole/min x mg
Lymphocytes Baseline Maximum EC50, nM TCDD
Humanb 2.8 ± 2.4 58.1 ± 52.0 1.8 ± 0.8
Murinec 0.4 ± 0.3 2.5 ± 0.6 1.3 ± 0.3
aC57BV6 splenic lymphocytes were isolated and cultured at 1 x 106
cells/mLinRPMI1640containing2%phytohemagglutinin(Gibco,Grand
Island, NY), 0.13% pokeweed mitogen (Gibco), 1 mM glutamine, and 5 x
10-5 M 3-mercaptoethanol for 3 days at 37°C in a 5% CO2 atmosphere.
Human peripheral blood lymphocytes were isolated using Leucoprep
tubes (Beckton Dickinson, Lincoln Park, NJ) by the manufacturers'
suggested method. The cells were cultured at 1 x 106 cells/mLin RPMI
1640containing 2%phytohemagglutinin, 0.13% pokeweed mitogen, and1
mM glutamine for 3 days at 37°C in a 5% CO2 atmosphere. Cultured
lymphocytes were exposed tovarious concentrations ofTCDD absorbed
intofetalcalfserum, aspreviouslydescribed(34).After3daysin culture,
the cells were assayed for EROD activity, as described by Thompson et
al. (35).
bDatarepresentmean ± SDforacohortof36individuals; inducibility
ofEROD activitywas replicated at least twice for each individual.
cData represent mean ± SD for five individual experiments.
Recently, Clark et al. (38) demonstrated that exposure to
such concentrations in vitro resulted in the dose-
dependent stimulation of tyrosine kinase activity in
murine lymphocytes. The finding that both human and
murinelymphocytesrespondtonanomolarconcentrations
ofTCDD suggests thatthe two species respond similarly.
Another important consideration for assessing human
risk for TCDD-mediated effects is interindividual dif-
ferences in response, perhaps related to genetic suscep-
tibility. As discussed above, the Ah receptor appears to
regulate differences in susceptibility to TCDD-mediated
effects in various strains of mice. Humans also demon-
strate interindividual differences in their responsiveness
to TCDD and related compounds. We have analyzed
CYPlAl induction by quantifying EROD activity in lym-
phocytes from a cohort of 36 individuals. Interindividual
variationinmaximalinductionofERODactivitybyTCDD
is shownin Figure2.Theresponses fallinto anessentially
bimodal or perhaps trimodal distribution, with approx-
imately 70% ofthe individuals having a low response and
30% responding with a high maximal EROD response.
This finding may be due to genetic differences in the
capacityofhuman cells tobeinducedbyTCDD.Anumber
of investigators have suggested that a high inducibility
phenotype for AHH induction may be associated with
increased susceptibility to lung cancer (39-41). Induction
of EROD activity in human lymphocytes in vitro may
thereforebeusefulforphenotypingindividualsforsuscep-
tibilitytoadversehumanhealtheffectsfollowingexposure
to TCDD or polycyclic aromatic hydrocarbons.
We have attempted to characterize inducibility phe-
notypesfurtherwithrestrictionfragmentlengthpolymor-
phism (RFLP) genotype analysis. Kawajiri et al. (42)
recently described an MspI polymorphism in the 3' non-
coding region of the CYPlAl gene that was associated
with increased risk for lung cancer. Petersen et al (43)
reported that in one family heterozygosity for this poly-
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morphism co-segregated with the AHH high-inducibility
phenotype. We have compared the EROD inducibility
phenotype Nith the CYPIAl MspI polymorphism in 19
individuals ancd found none to be homozygous for theMspI
site (MspI + / ). In thelow-inducibility group8% ('/12)were
heterozygous (MspI/-) while in the high inducibility
group 43% (77/) 7were heterozygous for the RFLP. In this
small group, there does appear to be an association
between the presence oftheMspI allele and EROD induc-
ibility; however, the mechanistic link between this poly-
mor-phism and EROD inducibility and its relationship to
other biological effects such as cancer remain unclear.
Patient#
681 682 709
In mice, allelic differences in the Ali receptor result in
strains with different susceptibilities to the toxic and
biochemical effects of TCDD (10,44). We are analyzing
human lymphocytes for levels of Ah receptor protein,
using photoaffinity ligands for the receptor, to determine
ifthere is an association between high inducibility andAll
receptor levels. Figure 3 is an autoradiograph of pho-
toaffinity labeled Ah receptor preparations from three
individuals. Different amounts of labeled protein were
electrophoresed inpolyacrylamide gels for each individual.
The amount of photoaffinity labeled Ali receptor was
related linearly to protein concentration under the condi-
Hopa 1
875 CelfLine
I Im 1 1
<' 95kDa
25 50 100 25 50 100 25 50 100 25 50 100 10 20
Protein (pg)
Fi(;vIIE 3. Relationship betwseen protein concentration an(l amount of A/i receptor in human lymlphocytes. A/i receptorl etermination: cytosols from
mitogen-stimiiulate(l human lynmphocyteswN-ereprepared in HEDGbuffer containing lmMphenylmethylsulfonyl fluoride, 2 iLg/mil, leupeptin, and 20 mM
so(liuiim molybolate by centrifugation at 100,000g. A/i receptor levels were quantified by photoaffinity labeling as pleviously (escribed by Polnd et al.
(45,4(;).
105kDa -
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tions of the assay. Intra-individual variation in receptor
preparations, however, limited our ability to draw conclu-
sions aboutreceptorexpression andits contribution tothe
phenotypic expression of EROD inducibility. We are now
investigatingfactors involved inAhreceptorexpression in
human lymphocytes and whether differences in receptor
concentration or affinity contribute to phenotypic induc-
ibility of CYPlAl activity. Interdividual differences in
human CYPlAl induction by TCDD may reflect both
polymorphismintheCYPlA4 geneaswellasdifferencesin
theAh receptor itself.
Relevance of Biomarkers to Risk
Assessment of TCDD
Considerable controversy surrounds the risk assess-
ment ofTCDD and its structural analogs (11,44), most of
whichisrelatedtotheselection ofriskassessmentmodels.
U.S. Federal agencies and countries that use the linear
multistage model have established considerably lower
acceptable daily intakes (ADIs) than countries that use
safety factor/threshold models. For example, the U.S.
Environmental Protection Agency's ADI for TCDD is a 6
fg/kg/day,whereas Canadahas setanADI of10,000fg/kg/
day.Thesediscrepancies, coupledwithourgrowingknowl-
edge ofthe mechanisms ofaction responsible forthe toxic
and biochemical effects ofTCDD, have provided impetus
for the generation of biologically-based risk assessment
models. Thesemodels arebased onthegenerallyaccepted
dogmathatmost, ifnotall, ofthe effects ofTCDD require
interactionwith theAh receptor; however, itmustbe kept
in mind that interaction ofTCDD with theAh receptor is
necessary but not sufficient to produce its effects.
When a simple relationship exists between receptor
occupancy and biological response, there is no threshold
for response (14,48). Such a situation may exist for induc-
tionCfCYPlA1 andCYP1A2.Forexample,extrapolationof
data on CYPlAl or CYP1A2 induction in our rat tumor
promotion model gives no evidence ofa threshold. There-
fore,ifCYPlAl isused as asurrogateforTCDD-mediated
cancer dose-response relationships, then the ADI (one
cancer in 106 individuals) would be similar to the current
U.S. standard of 6 fg/kg/day (49). If a threshold model is
employed in which CYPlAl induction is used as a surro-
gate for cancer, the following considerations emerge. The
currentlowestdetectable doseforinducingCYPlAl inrat
liver is 100 pg/kg/day (Table 1); we have preliminary data,
usingapolymerase chain reactionmethod, thatthelowest
detectable doseforCYPlAl inductioncouldbe aslowas10
pg/kg/day. If a 100-fold safety factor were employed, the
ADI would be 100 fg/kg/day; if a 1000-fold safety factor
were used, itwould 10 fg/kg/day.
Oneofthekeyissuesinriskassessmentistherelevance
ofthe animal dataforestimatinghuman risks. In the case
ofTCDD, our data provide strong evidence that humans
respond similarly to rats for many biochemical effects,
including CYPlAl induction. Although using CYPlAl
induction as a surrogate marker for cancer is simple and
attractive, the approach may be flawed. For example, we
have shown that dose-response relationships for TCDD-
mediated increases in hepatic cell proliferation and pre-
neoplastic lesions are very different from those for
CYPlAl induction. Increases in cell proliferation are
detected at much higher doses than those needed to
produce enzyme induction (lable 1). Analysis of the rat
tumor data suggests that CYPlAl induction may notbe a
good predictor of liver tumors. Finally, most TCDD risk
assessments have focused on cancer risk, whereas addi-
tional toxic responses, such as teratogenesis and immu-
notoxicity, should also be included in risk assessment
models for TCDD.
This manuscript was presented at the Conference on Biomonitoring
and Susceptibility Markers in Human Cancer: Applications in Molecular
Epidemiology and Risk Assessment that was held in Kailua-Kona,
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